| scholarly article | Q13442814 |
| P2093 | author name string | Andrea Giuffrida | |
| Alexandre Seillier | |||
| P2860 | cites work | Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain | Q22001491 |
| Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands | Q24311776 | ||
| N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo | Q24532188 | ||
| Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 | ||
| An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors | Q24534526 | ||
| Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha | Q24564778 | ||
| Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects | Q24569799 | ||
| The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors | Q24617322 | ||
| 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor | Q24620096 | ||
| Receptors for acylethanolamides-GPR55 and GPR119 | Q24647538 | ||
| Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay | Q24654730 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Anandamide and vanilloid TRPV1 receptors | Q24672354 | ||
| The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects | Q24681369 | ||
| Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism | Q24681426 | ||
| Novel cannabinoid receptors | Q24681482 | ||
| Evidence against the presence of an anandamide transporter | Q24683153 | ||
| Endocannabinoid signalling in the blood of patients with schizophrenia | Q24800061 | ||
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells | Q28212245 | ||
| Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor | Q28218654 | ||
| Cannabinoids and psychosis | Q28241328 | ||
| mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. | Q39917016 | ||
| Multiple pathways involved in the biosynthesis of anandamide | Q40106992 | ||
| Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells | Q40158906 | ||
| Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. | Q46624652 | ||
| Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol | Q46649583 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats | Q46747113 | ||
| Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. | Q47242856 | ||
| Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture | Q48088888 | ||
| Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens. | Q48118951 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures | Q48246173 | ||
| Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine | Q48286778 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. | Q48390432 | ||
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats | Q48485540 | ||
| Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia | Q48532654 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. | Q51902545 | ||
| Evolutionary origins of the endocannabinoid system | Q56899189 | ||
| A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats | Q60690596 | ||
| Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia | Q61413499 | ||
| Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 | ||
| Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. | Q64996366 | ||
| Elevated endogenous cannabinoids in schizophrenia | Q73029596 | ||
| Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? | Q73423096 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 | ||
| Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? | Q84611635 | ||
| Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. | Q40449973 | ||
| Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. | Q40677598 | ||
| The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism | Q40817229 | ||
| The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis | Q41147529 | ||
| Cell biology. Anatomy of prostaglandin signals | Q41541063 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. | Q41713139 | ||
| Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway | Q41791622 | ||
| A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist | Q42017075 | ||
| The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons | Q42110966 | ||
| Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats | Q42166759 | ||
| Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. | Q42454049 | ||
| Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia | Q42486484 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the cerebellum | Q42494226 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum | Q42523780 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 | ||
| Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system | Q42882543 | ||
| Regulation of plasticity of glutamate synapses by endocannabinoids and the cyclic-AMP/protein kinase A pathway in midbrain dopamine neurons | Q43055373 | ||
| Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. | Q43091758 | ||
| Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain | Q43235028 | ||
| Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats | Q43255656 | ||
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. | Q43266820 | ||
| Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. | Q43283706 | ||
| Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment | Q43299005 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. | Q43581230 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Unawareness of dyskinesias in Parkinson's and Huntington's diseases | Q43696853 | ||
| Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Q44086465 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease | Q44285779 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. | Q44524201 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry | Q44733045 | ||
| Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia | Q44748286 | ||
| Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | Q44885114 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. | Q45927862 | ||
| Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. | Q46205733 | ||
| Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia | Q46370479 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons | Q28245016 | ||
| Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors | Q28265832 | ||
| Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus | Q28268567 | ||
| Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 | ||
| Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides | Q28295481 | ||
| International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ | Q28298445 | ||
| Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons | Q28573124 | ||
| Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system | Q28590486 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| The molecular logic of endocannabinoid signalling | Q29615356 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens | Q30499463 | ||
| Animal models of neurological deficits: how relevant is the rat? | Q31091605 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. | Q31997655 | ||
| Identification and characterisation of a novel splice variant of the human CB1 receptor | Q33210400 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 | ||
| Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. | Q33636763 | ||
| Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol | Q33902321 | ||
| Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia | Q33932087 | ||
| The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors | Q33940288 | ||
| Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses | Q33940688 | ||
| Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex | Q34026425 | ||
| An endogenous cannabinoid (2-AG) is neuroprotective after brain injury | Q34093755 | ||
| Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research | Q34147040 | ||
| Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol | Q34165188 | ||
| A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats | Q34308648 | ||
| The role of glial cells in Parkinson's disease | Q34318207 | ||
| Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. | Q34320147 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| Evidence for novel cannabinoid receptors | Q34415409 | ||
| An endocannabinoid mechanism for stress-induced analgesia. | Q34428429 | ||
| Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex | Q34536072 | ||
| A second fatty acid amide hydrolase with variable distribution among placental mammals | Q34570802 | ||
| CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum | Q34605794 | ||
| Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression | Q34609936 | ||
| Transient receptor potential channels: targeting pain at the source | Q34912798 | ||
| Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration | Q34983386 | ||
| Cannabinoids and neuroinflammation | Q35046205 | ||
| Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS | Q35107820 | ||
| Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors | Q35202878 | ||
| Cellular accumulation of anandamide: consensus and controversy | Q35217244 | ||
| Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment | Q35611010 | ||
| Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation | Q35645037 | ||
| Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. | Q35688511 | ||
| The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 | ||
| New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia | Q35991093 | ||
| Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice | Q36020820 | ||
| Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. | Q36176523 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Cannabinoids and prefrontal cortical function: insights from preclinical studies | Q36436004 | ||
| Cannabinoid control of motor function at the basal ganglia. | Q36441208 | ||
| The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction | Q36478275 | ||
| Biochemistry and pharmacology of endovanilloids | Q36756199 | ||
| Cannabinoids and psychosis | Q36756388 | ||
| The endocannabinoid system and neurogenesis in health and disease. | Q36778571 | ||
| Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis | Q36869809 | ||
| Parkinson's disease: levodopa-induced dyskinesia and signal transduction. | Q37086131 | ||
| Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 | Q37132571 | ||
| Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity | Q37140712 | ||
| The cannabinoid system in Parkinson's disease: multiple targets to motor effects | Q37146722 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 | ||
| The therapeutic potential of novel cannabinoid receptors | Q37402927 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Presynaptic specificity of endocannabinoid signaling in the hippocampus | Q39750122 | ||
| Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. | Q39831177 | ||
| P433 | issue | 1 | |
| P921 | main subject | endocannabinoids | Q10483908 |
| P304 | page(s) | 51-58 | |
| P577 | publication date | 2012-04-10 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | New insights on endocannabinoid transmission in psychomotor disorders | |
| P478 | volume | 38 |
| Q37716381 | Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs |
| Q33819365 | Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. |
| Q90263481 | Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model |
| Q24623244 | Hub and switches: endocannabinoid signalling in midbrain dopamine neurons |
| Q27014154 | Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction |
| Q37309718 | Peripheral endocannabinoid system dysregulation in first-episode psychosis |
Search more.